STOCK TITAN

Ultragenyx (RARE) awards RSUs and stock options to executive Pinion

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Ultragenyx Pharmaceutical Inc. executive John Richard Pinion received new equity awards in the form of restricted stock units and stock options. He was granted 23,116 shares of common stock as RSUs under the company’s 2023 Incentive Plan, bringing his direct common stock holdings to 133,142 shares after the award. These RSUs vest in four equal annual installments on each anniversary of the grant date.

He also received a stock option covering 79,936 shares of common stock at an exercise price of $24.52 per share, expiring on April 16, 2036. One quarter of the option vests on the first anniversary of the grant date, with the remainder vesting in equal monthly installments over the following three years.

Positive

  • None.

Negative

  • None.
Insider Pinion John Richard
Role See Remarks
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) 79,936 $0.00 --
Grant/Award Common Stock 23,116 $0.00 --
Holdings After Transaction: Stock Option (Right to Buy) — 79,936 shares (Direct, null); Common Stock — 133,142 shares (Direct, null)
Footnotes (1)
  1. Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. On the first anniversary of the grant date of the option (the "Option Anniversary Date"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date.
RSU grant size 23,116 shares Restricted Stock Units granted under 2023 Incentive Plan
Option grant size 79,936 shares Stock option covering common stock
Option exercise price $24.52 per share Conversion or exercise price of stock option
Option expiration April 16, 2036 Expiration date of stock option grant
Shares held after grant 133,142 shares Total common stock held directly after RSU award
RSU vesting schedule 4 annual installments 1/4 vests on each anniversary of grant date
Option vesting schedule 1/4 yearly then monthly 1/4 at first anniversary, then 1/48 monthly thereafter
Restricted Stock Units ("RSUs") financial
"Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan."
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
2023 Incentive Plan financial
"Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan."
Stock Option (Right to Buy) financial
"Stock Option (Right to Buy) with an exercise price of 24.5200."
vesting conditions financial
"which are subject to certain vesting conditions."
Vesting conditions are the rules that determine when someone earning company stock or stock options actually gains the right to keep or sell them, typically based on staying with the company for a set time or meeting performance targets. Think of it like keys that unlock gradually — some unlock by calendar date, others only after agreed milestones. Investors care because vesting shapes management incentives, the timing of share sales, and the number of shares that can enter the market, which can affect a company's valuation and ownership mix.
grant date financial
"on each anniversary of the grant date, such that the RSUs are fully vested"
The grant date is the day a company formally gives an employee or contractor the right to receive stock-based compensation, such as stock options or restricted shares. It matters to investors because it fixes key terms—like the price, the start of the ownership clock, and when the award will affect the company’s financial statements and share count—so it can influence dilution, reported expenses, and potential future selling pressure.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Pinion John Richard

(Last)(First)(Middle)
C/O ULTRAGENYX PHARMACEUTICAL INC.
60 LEVERONI COURT

(Street)
NOVATO CALIFORNIA 94949

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Ultragenyx Pharmaceutical Inc. [ RARE ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
See Remarks
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
04/16/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock04/16/2026A23,116(1)A$0133,142(2)D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$24.5204/16/2026A79,936 (3)04/16/2036Common Stock79,936$079,936D
Explanation of Responses:
1. Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date
2. Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.
3. On the first anniversary of the grant date of the option (the "Option Anniversary Date"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date.
Remarks:
EVP, Chief Quality Operations Officer
/s/ Karah Parschauer, attorney-in-fact04/20/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider equity awards did Ultragenyx (RARE) report for John Richard Pinion?

Ultragenyx reported that John Richard Pinion received 23,116 restricted stock units and a stock option for 79,936 shares of common stock. Both awards were granted under the company’s 2023 Incentive Plan and are subject to multi-year vesting schedules tied to continued service.

How many Ultragenyx (RARE) shares does John Richard Pinion hold after this Form 4?

After the reported grant, John Richard Pinion directly holds 133,142 shares of Ultragenyx common stock. This figure reflects his ownership following the award of 23,116 restricted stock units, which are subject to vesting conditions before fully becoming unrestricted shares.

What are the vesting terms of the new Ultragenyx (RARE) RSU grant to John Richard Pinion?

The 23,116 restricted stock units vest in four equal annual installments. One quarter of the underlying shares vest on each anniversary of the grant date, so the RSUs are fully vested on the fourth anniversary, assuming continued satisfaction of the plan’s vesting conditions.

What are the key terms of the Ultragenyx (RARE) stock option granted to John Richard Pinion?

The stock option covers 79,936 shares of Ultragenyx common stock with an exercise price of $24.52 per share and expires on April 16, 2036. One quarter of the shares vest after one year, then the remaining portion vests in equal monthly installments over three years.

Is the Ultragenyx (RARE) Form 4 for John Richard Pinion a purchase or a compensation award?

The Form 4 reflects compensation-related equity awards, not an open-market share purchase. Both the 23,116 restricted stock units and the 79,936-share stock option were reported with code “A,” indicating a grant or award under Ultragenyx’s 2023 Incentive Plan.

Does the Ultragenyx (RARE) filing mention previously granted RSUs for John Richard Pinion?

Yes. The footnotes state that the reported holdings include previously reported shares of common stock underlying RSUs granted to John Richard Pinion. These earlier RSUs remain subject to their own vesting conditions under Ultragenyx’s equity compensation arrangements.